Eventide Asset Management, LLC 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 12:03 pm Sale | 2024-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Eventide Asset Management, LLC | 1,234,834 3.730% | -621,152 (-33.47%) | Filing |
| 2024-11-14 12:23 pm Sale | 2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Eventide Asset Management, LLC | 1,855,986 5.610% | -336,225 (-15.34%) | Filing |
| 2024-08-09 09:43 am Sale | 2024-07-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Eventide Asset Management, LLC | 2,192,211 6.650% | -810,620 (-27.00%) | Filing |
| 2023-12-11 5:13 pm Purchase | 2023-11-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Eventide Asset Management, LLC | 3,002,831 11.930% | 3,002,831 (New Position) | Filing |